A live-attenuated vaccine against SARS-CoV-2 coronavirus is being developed by Codagenix in collaboration with Serum Institute of India for COVID-2019 infections. Codagenix will make use of its proprietary deoptimisation technology to synthesize the live-attenuated vaccine. The technology helps in generating multiple vaccine candidates against viruses and just requires the digital sequence of the viral genome. Viral genomes are processed by Codagenix’s computer-based algorithm for inducing multiple silent mutations into the genome to use codon pairs that are underrepresented in human cells. The genome that is de-optimised for translation in the human host cell is synthesised from scratch, assembled into a whole genome, transfected into cells and live, “de-optimised”, attenuated viruses are recovered for animal studies. The vaccine can be useful against multiple antigens of the virus and has the ability to scale for mass production. Early research is underway in the US.
In February 2020, Codagenix entered into a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the COVID-2019 infections. Codagenix has designed multiple nCoV vaccine candidate genomes using its proprietary deoptimisation technology. The vaccine viruses will be grown and tested in vivo by contracted laboratories suitable for containment, prior to testing in clinical trials. The Serum Institute of India will then scale-up the manufacture of the vaccine to ensure its availability to meet a critical public health need. Codagenix and Serum Institute are pursuing an accelerated development pathway with built-in redundancies to increase speed and likelihood of success. 
Key Development Milestones
As of February 2020, Codagenix has designed several genomes for the coronavirus vaccine candidate  .